EXELIXIS, INC. - 8-K Filing
FDA extended review period for Exelixis' NDA for zanzalintinib to March 3, 2027 (Items: 8.01 Other Events)
Tickers: $EXEL
More Regulatory news
- AMTECH SYSTEMS INC - 8-K Filing
- REGIONAL HEALTH PROPERTIES, INC - 8-K Filing
- Bitwise Avalanche ETF - 8-K Filing
- MiNK Therapeutics, Inc. - 10-Q Filing
- Future Vision II Acquisition Corp. - 10-Q Filing
- THUNDER MOUNTAIN GOLD INC - 10-Q Filing
- MiNK Therapeutics, Inc. - 8-K Filing
- SusGlobal Energy Corp. - 10-Q Filing
- Ideal Power Inc. - 8-K Filing
- DIGI INTERNATIONAL INC - 8-K Filing